Objective: To introduce inhaled iloprost for the treatment of primary pulmonary hypertension.
前言：目的：介绍治疗原发性肺动脉高压的吸入性伊洛前列素。
Dyspnoea measures were similar between placebo and iloprost at baseline and at the end of therapy.
在治疗初始和终末呼吸困难评估在安慰剂组和伊洛前列素组之间类似。
Otherwise no unexpected adverse effects were seen in the trial beyond those reported previously for iloprost.
在试验中既往报道有关的伊洛前列素并无意外不良反应出现。
No significant differences in efficacy were found between iloprost and placebo, either overall or at any time point in the study.
这项研究在任何时点以及整个试验中显示伊洛前列素和安慰剂组之间疗效并无显著差别。
Results and Conclusion: Inhaled iloprost can reduce pulmonary vascular resistance and delay the development of primary pulmonary hypertension.
结果和结论：吸入性伊洛前列素治疗可以降低肺血管阻力和延缓原发性肺动脉高压的进程。
Cardiac catheterization, standard lung function testing before and after iloprost inhalation, 6-min walk test, World Health Organization functional class, and hemodynamic parameters were monitored.
研究监测了吸入前后的心导管检查、标准肺功能检查，6分钟步行实验、世界卫生组织功能分级和血流动力学指标。
Cardiac catheterization, standard lung function testing before and after iloprost inhalation, 6-min walk test, World Health Organization functional class, and hemodynamic parameters were monitored.
研究监测了吸入前后的心导管检查、标准肺功能检查，6分钟步行实验、世界卫生组织功能分级和血流动力学指标。
应用推荐